Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.
Sampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients in routine practice | Patients prescribed Champix by treating physician and then entered into trial |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| varenicline | Drug | Champix will be prescribed as per usual practice and at the sole discretion of the physician |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Smoking Abstinence at Week 12 | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. | Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Smoking Abstinence Before Last Observed Study Visit | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. |
| Measure | Description | Time Frame |
|---|---|---|
| Varenicline Prescription Status | Prescribed status was assessed using the following question in consent record form: Would a maintenance period of the drug be prescribed to the participant after this study ends (Yes/No). Missing values were recorded as 'unknown'. | After last observed study visit (Week 12 or ET) |
| Average Daily Dose of Varenicline |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study is in Asian patients. The patients enrolled should be of legal adult age who regularly smoke and whose main tobacco product is cigarettes. The patients must be willing to make an attempt to stop smoking.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Beijing | Beijing Municipality | 100029 | China | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
A total of 1429 participants were screened for this study and 1377 participants were assigned to the study treatment.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Varenicline | Varenicline 0.5 mg once daily orally from Day 1 and titrated up to 1 mg dose twice daily (BID) from Day 8 till Week 12 or Last Observed Study Visit. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Last observed study visit (Week 12 or early termination [ET]) |
| Percentage of Participants With Smoking Abstinence Status From Week 3 to Week 11 | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. | Week 3 through Week 11 |
| CO Level at Last Observed Study Visit | The CO level was measured from exhaled air of the participant using CO analyzer at the last observed study visit which was the last available CO level recorded after baseline. The CO level was only measured if it was a part of the usual practice at the site. | Last observed study visit (Week 12 or ET) |
| Average Weekly Number of Cigarettes Smoked at Last Observed Study Visit | The average number of cigarettes smoked per day over the last 7 days was collected as a part of nicotine use inventory assessment through consent record form module which included a questionnaire: Did the participant smoke any cigarettes (even a puff) in last 7 days (Yes/No) and Did the participant use any other tobacco products (example- pipe, cigars, chew, snuff) in last 7 days (Yes/No). | Last observed study visit (Week 12 or ET) |
| Days 1-3, Days 4-7, Day 8 through last observed study visit (Week 12 or ET) |
| Median Duration of Treatment of Varenicline | The duration was defined as the total number of dosing days from first to last day of each study treatment. | Baseline through last observed study visit (Week 12 or ET) |
| Concomitant Drug Treatments | Baseline through Last observed study visit (Week 12 or ET) |
| Beijing |
| Beijing Municipality |
| 100083 |
| China |
| Pfizer Investigational Site | Beijing | Beijing Municipality | 100191 | China |
| Pfizer Investigational Site | Guangzhou | Guangdong | 510080 | China |
| Pfizer Investigational Site | Guangzhou | Guangdong | 510150 | China |
| Pfizer Investigational Site | Guangzhou | Guangdong | 510515 | China |
| Pfizer Investigational Site | Shenzhen | Guangdong | 518020 | China |
| Pfizer Investigational Site | Wuhan | Hubei | 430060 | China |
| Pfizer Investigational Site | Changsha | Hunan | 410006 | China |
| Pfizer Investigational Site | Nanjing | Jiangsu | 210009 | China |
| Pfizer Investigational Site | Suzhou | Jiangsu | 215004 | China |
| Pfizer Investigational Site | Shenyang | Liaoning | 110000 | China |
| Pfizer Investigational Site | Shenyang | Liaoning | 110016 | China |
| Pfizer Investigational Site | Shenyang | Liaoning | 110024 | China |
| Pfizer Investigational Site | Shenyang | Liaoning | 110042 | China |
| Pfizer Investigational Site | Xi'an | Shaanxi | 710004 | China |
| Pfizer Investigational Site | Xi'an | Shaanxi | 710032 | China |
| Pfizer Investigational Site | Xi'an | Shaanxi | 710038 | China |
| Pfizer Investigational Site | Xi'an | Shaanxi | 710068 | China |
| Pfizer Investigational Site | Taiyuan | Shanxi | 030012 | China |
| Pfizer Investigational Site | Chengdu | Sichuan | 610041 | China |
| Pfizer Investigational Site | Tianjin | Tianjin Municipality | 300192 | China |
| Pfizer Investigational Site | Beijing | 100020 | China |
| Pfizer Investigational Site | Beijing | 100029 | China |
| Pfizer Investigational Site | Beijing | 100036 | China |
| Pfizer Investigational Site | Beijing | 100038 | China |
| Pfizer Investigational Site | Beijing | 100039 | China |
| Pfizer Investigational Site | Beijing | 100045 | China |
| Pfizer Investigational Site | Beijing | 100050 | China |
| Pfizer Investigational Site | Beijing | 100091 | China |
| Pfizer Investigational Site | Beijing | 100096 | China |
| Pfizer Investigational Site | Beijing | 100730 | China |
| Pfizer Investigational Site | Beijing | 100853 | China |
| Pfizer Investigational Site | Nanning | 530021 | China |
| Pfizer Investigational Site | Shanghai | 200025 | China |
| Pfizer Investigational Site | Shanghai | 200031 | China |
| Pfizer Investigational Site | Shanghai | 200032 | China |
| Pfizer Investigational Site | Shanghai | 200040 | China |
| Pfizer Investigational Site | Shanghai | 200065 | China |
| Pfizer Investigational Site | Shanghai | 200072 | China |
| Pfizer Investigational Site | Shanghai | 200080 | China |
| Pfizer Investigational Site | Shanghai | 200233 | China |
| Pfizer Investigational Site | Shanghai | 200433 | China |
| Pfizer Investigational Site | Shanghai | 201203 | China |
| Pfizer Investigational Site | Shijiazhuang | 050011 | China |
| Pfizer Investigational Site | Tianjin | 300051 | China |
| Pfizer Investigational Site | Tianjin | 300162 | China |
| Pfizer Investigational Site | Tianjin | 300280 | China |
| Pfizer Investigational Site | Wuhan | 430022 | China |
| Pfizer Investigational Site | Hyderabad | Andhra Pradesh | 500029 | India |
| Pfizer Investigational Site | Ahmedabad | Gujarat | 380005 | India |
| Pfizer Investigational Site | Kochi | Kerala | 682026 | India |
| Pfizer Investigational Site | Tthiruvananthapuram | Kerala | 695504 | India |
| Pfizer Investigational Site | Mumbai | Maharashtra | 400 022 | India |
| Pfizer Investigational Site | Mumbai | Maharashtra | 400 070 | India |
| Pfizer Investigational Site | Mumbai | Maharashtra | 400008 | India |
| Pfizer Investigational Site | Mumbai | Maharashtra | 400036 | India |
| Pfizer Investigational Site | Delhi | National Capital Territory of Delhi | 110088 | India |
| Pfizer Investigational Site | New Delhi | National Capital Territory of Delhi | 110 076 | India |
| Pfizer Investigational Site | Daryāganj | New Delhi | 110 002 | India |
| Pfizer Investigational Site | Delhi | New Delhi | 110017 | India |
| Pfizer Investigational Site | Delhi | New Delhi | 110027 | India |
| Pfizer Investigational Site | Delhi | New Delhi | 110085 | India |
| Pfizer Investigational Site | New Delhi | New Delhi | 110 016 | India |
| Pfizer Investigational Site | Coimbatore | Tamil Nadu | 641045 | India |
| Pfizer Investigational Site | Chennai | 600 032 | India |
| Pfizer Investigational Site | San Juan City | Batangas | Philippines |
| Pfizer Investigational Site | Batac | Ilocos Norte | 2906 | Philippines |
| Pfizer Investigational Site | San Fernando City | La Union | 2500 | Philippines |
| Pfizer Investigational Site | Angeles City | Pampanga | Philippines |
| Pfizer Investigational Site | Urdaneta | Pangasinan | Philippines |
| Pfizer Investigational Site | Tarlac City | Tarlac | Philippines |
| Pfizer Investigational Site | Davao City | 8000 | Philippines |
| Pfizer Investigational Site | Marikina City | Philippines |
| Pfizer Investigational Site | Pasay | 1301 | Philippines |
| Pfizer Investigational Site | Quezon City | 1100 | Philippines |
| Pfizer Investigational Site | Quezon City | 1103 | Philippines |
| Pfizer Investigational Site | Quezon City | Philippines |
| Pfizer Investigational Site | Cheonan-si | Chungcheongnam-do | 330-715 | South Korea |
| Pfizer Investigational Site | Goyang-si | Gyeonggi-do | 411-719 | South Korea |
| Pfizer Investigational Site | Seongnam-si | Gyeonggi-do | 463-707 | South Korea |
| Pfizer Investigational Site | Suwon | Gyeonggi-do | 442-723 | South Korea |
| Pfizer Investigational Site | Yangsan | Gyeongsangnam-do | 626-770 | South Korea |
| Pfizer Investigational Site | Iksan-Si | Jeollabuk-do | 570-711 | South Korea |
| Pfizer Investigational Site | Daegu | 700-712 | South Korea |
| Pfizer Investigational Site | Daegu | 705-717 | South Korea |
| Pfizer Investigational Site | Daegu | 705-718 | South Korea |
| Pfizer Investigational Site | Daejeon | 301-721 | South Korea |
| Pfizer Investigational Site | Daejeon | 301-804 | South Korea |
| Pfizer Investigational Site | Incheon | 403-720 | South Korea |
| Pfizer Investigational Site | Incheon | 405-760 | South Korea |
| Pfizer Investigational Site | Seoul | 110-744 | South Korea |
| Pfizer Investigational Site | Seoul | 120-752 | South Korea |
| Pfizer Investigational Site | Seoul | 137-701 | South Korea |
| Pfizer Investigational Site | Seoul | 138-736 | South Korea |
| Pfizer Investigational Site | Seoul | South Korea |
| Pfizer Investigational Site | Suwon | 443-721 | South Korea |
| Treated |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Varenicline | Varenicline 0.5 mg once daily orally from Day 1 and titrated up to 1 mg dose twice daily (BID) from Day 8 till Week 12 or Last Observed Study Visit. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| ||||||||||||||||||||||
| Sex/Gender, Customized | Number | Participants |
| |||||||||||||||||||||||
| Smoking history: Total number of years participant smoked | N = 1308 for the parameter analyzed. | Median | Full Range | Years |
| |||||||||||||||||||||
| Smoking history: Average number of cigarettes smoked per day in the last year | N = 1299 for the parameter analyzed. | Median | Full Range | cigarettes |
| |||||||||||||||||||||
| Smoking history: Longest period of abstinence in the last year | N = 1269 for the parameter analyzed. | Median | Full Range | Days |
| |||||||||||||||||||||
| Smoking history : Number of times the participant has attempted to quit in past year | N = 1257 for the parameter analyzed. Scores were graded as none [(no attempt) to 3 or more attempts]. | Median | Full Range | Quit attempts |
| |||||||||||||||||||||
| Smoking history : Participant categorized based on number of attempt to quit in the past year | N = 1257 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Smoking history : Did participant live with someone who smoked | N = 1287 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Smoking history : Did participant have frequent contact with someone who smoked | N = 1270 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Smoking history: Lifetime serious quit attempts | A serious quit attempt was defined as smoking cessation for more than 24 hours. Scores were graded as none (no attempt) to 3 or more attempts). N = 649 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Quit History : Main reasons for relapses after previous attempts | N = 813 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Quit History : Reasons motivated participant to quit smoking | N = 1299 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Fagerstrom Test of Nicotine Dependence (FTND) | FTND was designed to provide measure of nicotine dependence related to cigarette smoking. It contains 4 yes-no and 2 multiple choice questions. Items are scored 0-3 for multiple choice items, items are summed to yield total score of 0-10 (0=minimum to 10=maximum nicotine dependence).N= 268 for the parameter analyzed. | Mean | Standard Deviation | Scores on a scale |
| |||||||||||||||||||||
| Exhaled Carbon monoxide (CO) level | The CO level was measured from exhaled air of the participant using CO analyzer at the last observed study visit which was the last available CO level recorded after baseline. The CO level was only measured if it was a part of the usual practice at the site. N= 361 for the parameter analyzed. | Mean | Standard Deviation | parts per million (ppm) |
| |||||||||||||||||||||
| Average number of cigarettes smoked per day in the previous 7 day period at baseline | The average number of cigarettes smoked per day over the last 7 days was collected as a part of nicotine use inventory assessment through consent record form module which included a questionnaire: Did the participant smoke any cigarettes (even a puff) in last 7 days (Yes/No) and Did the participant use any other tobacco products (example- pipe, cigars, chew, snuff) in last 7 days (Yes/No). N=1256 for the parameter analyzed. | Median | Full Range | cigarettes |
| |||||||||||||||||||||
| Smoking related concurrent diseases | The 'n' is signifying those participants who were evaluated for this measure respectively. | Number | participants |
| ||||||||||||||||||||||
| Cardiovascular risk factors | N=138 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Participant social status : Current Marital Status | N = 1258 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Participant social status : Current Living Situation | N = 1243 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Healthcare utilization status: Reimbursement type | N=1287 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Health care utilization: Employment status | N=1266 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Family history of mental illness | Family members who were considered for the following parameter were Biological Parents, Biological Siblings, Children and Grandparents. The 'n' is signifying those participants who were evaluated for this measure respectively. | Number | participants |
| ||||||||||||||||||||||
| Nondrug treatments / procedures for primary diagnosis | N=701 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Prior Drug Treatment | N=435 for the parameter analyzed. | Number | participants |
| ||||||||||||||||||||||
| Medical History | N=129 for the parameter analyzed. | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Smoking Abstinence at Week 12 | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. | Full analysis set (FAS) included all participants who received at least 1 dose of study medication | Posted | Number | 95% Confidence Interval | percentage of participants | Week 12 |
|
|
| |||||||||||||||||||||||||
| Secondary | Percentage of Participants With Smoking Abstinence Before Last Observed Study Visit | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. | FAS included all participants who received at least 1 dose of study medication. | Posted | Number | 95% Confidence Interval | percentage of participants | Last observed study visit (Week 12 or early termination [ET]) |
|
| ||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Smoking Abstinence Status From Week 3 to Week 11 | Four criteria used for derivation of smoking abstinence status: if participant smoked any cigarettes (even a puff) in last 7 days (Yes/No); if participant used any other tobacco products in last 7 days (Yes/No); average number of cigarettes smoked per day over last 7 days (in cigarettes/day); CO level (positive: if more than 10 ppm; negative : if 0-10 ppm).Smoking abstinence status was determined as: smoking: if participant responded positively to at least 1 of above 4; quit: if participant responded negatively to all 4; unknown: if participant had missing information for all 4. | At Week t (t = 3 to 11), the analysis population was "Observed Cases minus Week t" (OC minus Week t), that is (i-e), participants in FAS excluding missing values at the time point in question where OC was the subset of participants in FAS with observed (not missing) values. | Posted | Number | percentage of participants | Week 3 through Week 11 |
|
| |||||||||||||||||||||||||||
| Secondary | CO Level at Last Observed Study Visit | The CO level was measured from exhaled air of the participant using CO analyzer at the last observed study visit which was the last available CO level recorded after baseline. The CO level was only measured if it was a part of the usual practice at the site. | FAS population included all participants who received at least 1 dose of study medication during study. Missing observations were not imputed and hence the participants analyzed were those without missing values (N=115). | Posted | Mean | Standard Deviation | ppm | Last observed study visit (Week 12 or ET) |
|
| ||||||||||||||||||||||||||
| Secondary | Average Weekly Number of Cigarettes Smoked at Last Observed Study Visit | The average number of cigarettes smoked per day over the last 7 days was collected as a part of nicotine use inventory assessment through consent record form module which included a questionnaire: Did the participant smoke any cigarettes (even a puff) in last 7 days (Yes/No) and Did the participant use any other tobacco products (example- pipe, cigars, chew, snuff) in last 7 days (Yes/No). | FAS population included all participants who received at least 1 dose of study medication during study. Missing observations were not imputed and hence the participants analyzed were those without missing values (N=518). | Posted | Median | Full Range | cigarettes | Last observed study visit (Week 12 or ET) |
|
| ||||||||||||||||||||||||||
| Other Pre-specified | Varenicline Prescription Status | Prescribed status was assessed using the following question in consent record form: Would a maintenance period of the drug be prescribed to the participant after this study ends (Yes/No). Missing values were recorded as 'unknown'. | FAS population included all participants who received at least 1 dose of study medication. | Posted | Number | participants | After last observed study visit (Week 12 or ET) |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Average Daily Dose of Varenicline | FAS population included all participants who received at least 1 dose of study treatment. Missing values were excluded from analysis. The 'n' is signifying those participants who received study drug and were evaluated for this measure at the timepoint for each group respectively. | Posted | Median | Full Range | mg | Days 1-3, Days 4-7, Day 8 through last observed study visit (Week 12 or ET) |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Median Duration of Treatment of Varenicline | The duration was defined as the total number of dosing days from first to last day of each study treatment. | FAS population included all participants who received at least 1 dose of study treatment. Missing values were excluded from analysis. | Posted | Median | Full Range | Days | Baseline through last observed study visit (Week 12 or ET) |
|
| ||||||||||||||||||||||||||
| Other Pre-specified | Concomitant Drug Treatments | FAS included all participants who received at least 1 dose of study medication. | Posted | Number | Participants | Baseline through Last observed study visit (Week 12 or ET) |
|
|
Not provided
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Varenicline | Varenicline 0.5 mg once daily orally from Day 1 and titrated up to 1 mg dose twice daily (BID) from Day 8 till Week 12 or Last Observed Study Visit. | 11 | 1,373 | 379 | 1,373 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute myocardial infarction | Cardiac disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Cor pulmonale chronic | Cardiac disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Colonic polyp | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Bronchiectasis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Haemorrhagic fever | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Acute stress disorder | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hearing impaired | Ear and labyrinth disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Vision blurred | Eye disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Abdominal distension | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Epigastric discomfort | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Eructation | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Flatulence | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Gastric disorder | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hyperchlorhydria | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Paraesthesia oral | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Periodontitis | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Regurgitation | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Chest pain | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hunger | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Irritability | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Malaise | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Otitis media chronic | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Pharyngitis | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dislocation of vertebra | Injury, poisoning and procedural complications | MedDRA 13.1 | Non-systematic Assessment |
| |
| Drug exposure during pregnancy | Injury, poisoning and procedural complications | MedDRA 13.1 | Non-systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA 13.1 | Non-systematic Assessment |
| |
| Weight increased | Investigations | MedDRA 13.1 | Non-systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hyperlipidaemia | Metabolism and nutrition disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Increased appetite | Metabolism and nutrition disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Tenosynovitis | Musculoskeletal and connective tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Disturbance in attention | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hypersomnia | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hypogeusia | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Lethargy | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Poor quality sleep | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Abnormal dreams | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Aggression | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Anxiety disorder | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Bradyphrenia | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Emotional disorder | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Euphoric mood | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Impatience | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Listless | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Restlessness | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Sleep disorder | Psychiatric disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Albuminuria | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Polyuria | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Renal pain | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Urinary hesitation | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Urinary tract disorder | Renal and urinary disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Erectile dysfunction | Reproductive system and breast disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Menopausal symptoms | Reproductive system and breast disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Sputum increased | Respiratory, thoracic and mediastinal disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Eczema | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Neurodermatitis | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Essential hypertension | Vascular disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hot flush | Vascular disorders | MedDRA 13.1 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 13.1 | Non-systematic Assessment |
|
Outcome measures were not designated as primary or secondary measures as this study was a post-marketing, prospective, non-comparative and non-interventional study.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068580 | Varenicline |
| ID | Term |
|---|---|
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D011810 | Quinoxalines |
Not provided
Not provided
| Unspecified |
|
| Two |
|
| Three or more |
|
| Two |
|
| Three or more |
|
| Urge to smoke is too strong |
|
| Weight gain |
|
| Exposure to smoke environment |
|
| Money / cost |
|
| Body image / appearance |
|
| Smoking ban in public places |
|
| Unspecified |
|
| History of microalbuminuria |
|
| Documented Ankle Brachial Index (ABI) <0.9 |
|
| Divorced |
|
| Widowed |
|
| Separated |
|
| Cohabitating |
|
| Living alone |
|
| Living in residential treatment center |
|
| Living in institution |
|
| Other unspecified |
|
| Public Insurance |
|
| Other unspecified |
|
| Part-time employed |
|
| Dementia (n=120) |
|
| Depression (Chronic or recurrent) (n=119) |
|
| Dissociative disorder (n=1) |
|
| Major depression (n=120) |
|
| Mental disorder (n=1) |
|
| Nicotine addiction (n=8) |
|
| Parkinson's disease (n=1) |
|
| Schizophrenia (n=120) |
|
| Other unspecified |
|
| Aceclofenac |
|
| Acetylcarnitine |
|
| Acetylcysteine |
|
| Acetylsalicylic acid |
|
| Acetylsalicylic acid/atorvastatin/ramipril |
|
| Acetylsalicylic acid/clopidogrel |
|
| Adenine/biphenyldimethyldicarboxylate/vitamins |
|
| Alfuzosin |
|
| All other therapeutic products |
|
| Allopurinol |
|
| Almagate |
|
| Alprazolam |
|
| Ambroxol |
|
| Ambroxol acefyllinate |
|
| Ambroxol hydrochloride |
|
| Aminophylline |
|
| Amisulpride |
|
| Amitriptyline hydrochloride |
|
| Amlodipine |
|
| Amlodipine besilate |
|
| Amlodipine besilate/atorvastatin calcium |
|
| Amlodipine besylate/valsartan |
|
| Amlodipine camsilate |
|
| Amlodipine maleate |
|
| Amlodipine orotate |
|
| Amlodipine/valsartan |
|
| Amoxicillin |
|
| Amoxicillin sodium |
|
| Antisterone |
|
| Aripiprazole |
|
| Aronamin gold |
|
| Arotinolol hydrochloride |
|
| Artemisia asiatica |
|
| Artemisia asiatica/ethanol |
|
| Asmeton |
|
| Atenolol |
|
| Atorvastatin |
|
| Atorvastatin calcium |
|
| Azathioprine |
|
| Azelastine |
|
| Azelastine hydrochloride |
|
| Azithromycin |
|
| Aztreonam |
|
| B-komplex "leciva" |
|
| Bambuterol hydrochloride |
|
| Becosules syrup |
|
| Becosym forte |
|
| Becotal |
|
| Benazepril |
|
| Benazepril hydrochloride |
|
| Benproperine |
|
| Benproperine phosphate |
|
| Bepotastine besilate |
|
| Beraprost |
|
| Betahistine |
|
| Bevantolol |
|
| Biphenyl dimethyl dicarboxylate/garlic |
|
| Biselect |
|
| Bismuth subcitrate tripotassium |
|
| Bismuth subcitrate tripotassium/ranitidine HCl |
|
| Bisoprolol |
|
| Bisoprolol fumarate |
|
| Borneol/notoginseng/salvia miltiorrhiza |
|
| Bromelains/dehydrocholic/pancreatin/simeticone |
|
| Broncho-vaxom |
|
| Budesonide |
|
| Bupropion |
|
| Bupropion hydrochloride |
|
| Buspiron |
|
| Buspirone |
|
| Calcium chloride |
|
| Calcium citrate/colecalciferol |
|
| Calcium lactate |
|
| Candesartan |
|
| Candesartan cilexetil |
|
| Carbazochrome |
|
| Cardiovascular system drugs |
|
| Carvedilol |
|
| Cefaclor |
|
| Cefoperazone sodium |
|
| Cefpodoxime |
|
| Cefpodoxime proxetil |
|
| Cefradine |
|
| Ceftriaxone sodium |
|
| Cefuroxime |
|
| Cefuroxime sodium |
|
| Cephalosporins and related substances |
|
| Cetirizine |
|
| Chlormadinone acetate |
|
| Choline alfoscerate |
|
| Chondroitin/glucosamine |
|
| Cilazapril |
|
| Cilnidipine |
|
| Cilostazol |
|
| Cimetidine |
|
| Ciprofloxacin |
|
| Citalopram |
|
| Clarithromycin |
|
| Clobazam |
|
| Clonazepam |
|
| Clopidogrel |
|
| Clopidogrel sulfate |
|
| Co-diovan |
|
| Colchicine |
|
| Cordalin /old form |
|
| Cough syrup |
|
| Dexamethasone |
|
| Dexamethasone/neomycin sulfate/polymyxin B sulfate |
|
| Diacerein |
|
| Diazepam |
|
| Diclofenac |
|
| Digoxin |
|
| Dihydrocodeine bitartrate |
|
| Diltiazem |
|
| Diltiazem hydrochloride |
|
| Dimenhydrinate |
|
| Diprophylline |
|
| Disulfiram |
|
| Domperidone |
|
| Donepezil |
|
| Doxazosin mesilate |
|
| Doxofylline |
|
| Drug, unspecified |
|
| Duloxetine hydrochloride |
|
| Ecabet monosodium |
|
| Efavirenz/emtricitabine/tenofovir |
|
| Efonidipine |
|
| Enalapril |
|
| Enalapril maleate |
|
| Enzymes |
|
| Epoprostenol |
|
| Eprosartan |
|
| Eprosartan mesilate |
|
| Eprosartan mesilate/hydrochlorothiazide |
|
| Erdosteine |
|
| Ergenyl chrono |
|
| Erlotinib hydrochloride |
|
| Erythromycin ethylsuccinate |
|
| Escitalopram |
|
| Esomeprazole |
|
| Esomeprazole magnesium |
|
| Etizolam |
|
| Etoposide |
|
| Etoricoxib |
|
| Ezetimibe |
|
| Ezetimibe/simvastatin |
|
| Famotidine |
|
| Felodipine |
|
| Fenofibrate |
|
| Ferric hydroxide polymaltose complex |
|
| Ferrous sulfate |
|
| Fexofenadine |
|
| Fish oil |
|
| Flumazenil |
|
| Flunarizine |
|
| Fluoxetine |
|
| Folic acid |
|
| Formoterol |
|
| Formoterol fumarate |
|
| Fosinopril |
|
| Fosinopril sodium |
|
| Furosemide |
|
| Gabapentin |
|
| Gefarnate |
|
| General nutrients/herbal NOS |
|
| Ginkgo biloba |
|
| Glibenclamide |
|
| Gliclazide |
|
| Glimepiride |
|
| Glimepiride/metformin hydrochloride |
|
| Glipizide |
|
| Gliquidone |
|
| Glucose |
|
| Glyceryl trinitrate |
|
| Guaifenesin |
|
| Hedera helix |
|
| Herbal preparation |
|
| Homeopatic preparation |
|
| Hyaluronate sodium |
|
| Hydrochlorothiazide |
|
| Hydrocortisone |
|
| Hydrotalcite |
|
| Hyzaar |
|
| Indapamide |
|
| Indometacin |
|
| Infliximab |
|
| Inosine |
|
| Insulin |
|
| Insulin aspart |
|
| Insulin glargine |
|
| Insulin glulisine |
|
| Insulin human |
|
| Insulin human injection, isophane |
|
| Ipratropium |
|
| Ipratropium bromide |
|
| Irbesartan |
|
| Isosorbide dinitrate |
|
| Isosorbide mononitrate |
|
| Isotretinoin |
|
| Itavastatin |
|
| Itopride |
|
| Itopride hydrochloride |
|
| Karvea hct |
|
| Kombipak II |
|
| Lacidipine |
|
| Lactitol |
|
| Lamivudine |
|
| Lansoprazole |
|
| Lekovit Ca |
|
| Lercanidipine |
|
| Lercanidipine hydrochloride |
|
| Levamlodipine besylate |
|
| Levocloperastine fendizoate |
|
| Levodropropizine |
|
| Levofloxacin |
|
| Levofloxacin hydrochloride |
|
| Levosalbutamol hydrochloride |
|
| Levosulpiride |
|
| Levothyroxine sodium |
|
| Liquorice |
|
| Lisinopril |
|
| Lithium carbonate |
|
| Loratadine |
|
| Lorazepam |
|
| Losartan |
|
| Losartan potassium |
|
| Magnesium hydroxide |
|
| Mecobalamin |
|
| Medilac-S |
|
| Mesalazine |
|
| Metformin |
|
| Metformin hydrochloride |
|
| Metformin hydrochloride/rosiglitazone |
|
| Metformin hydrochloride/sitagliptin |
|
| Methoxyphenamine |
|
| Methylprednisolone |
|
| Metoprolol |
|
| Metoprolol succinate |
|
| Metoprolol tartrate |
|
| Midazolam |
|
| Milnacipran hydrochloride |
|
| Mirtazapine |
|
| Molsidomine |
|
| Mometasone |
|
| Montelukast |
|
| Montelukast sodium |
|
| Mosapride |
|
| Mosapride citrate |
|
| Moxifloxacin hydrochloride |
|
| Multivitamins, plain |
|
| Myrtol |
|
| Naltrexone |
|
| Nateglinide |
|
| Nebivolol |
|
| Nicorandil |
|
| Nicotinic acid |
|
| Nifedipine |
|
| Nimodipine |
|
| Nisoldipine |
|
| Nitrendipine |
|
| Olanzapine |
|
| Olmesartan |
|
| Omega-3 marine triglycerides |
|
| Omega-3 triglycerides |
|
| Omeprazole |
|
| Orlistat |
|
| Oxazepam |
|
| Oxcarbazepine |
|
| Oxycodone hydrochloride |
|
| Pantoprazole |
|
| Pantoprazole sodium |
|
| Paracetamol |
|
| Paroxetine |
|
| Paroxetine hydrochloride |
|
| Penicillin NOS |
|
| Perindopril |
|
| Pethidine hydrochloride |
|
| Phenytoin sodium |
|
| Phosphatidyl choline |
|
| Pioglitazone |
|
| Pioglitazone hydrochloride |
|
| Pip/tazo |
|
| Platelets, human blood |
|
| Polycarbophil calcium |
|
| Pranlukast hydrate |
|
| Pravastatin |
|
| Pravastatin sodium |
|
| Prednisolone |
|
| Pregabalin |
|
| Procaterol |
|
| Propranolol |
|
| Propranolol hydrochloride |
|
| Pseudoephedrine hydrochloride |
|
| Pyridoxine hydrochloride |
|
| Quetiapine fumarate |
|
| Rabeprazole |
|
| Rabeprazole sodium |
|
| Ramipril |
|
| Ranitidine |
|
| Ranitidine hydrochloride |
|
| Rebamipide |
|
| Repaglinide |
|
| Risedronic acid |
|
| Risperidone |
|
| Rosiglitazone maleate |
|
| Rosuvastatin |
|
| Rosuvastatin calcium |
|
| Roxithromycin |
|
| Salbutamol |
|
| Salbutamol sulfate |
|
| Salmeterol |
|
| Salmeterol xinafoate |
|
| Salvia miltiorrhiza |
|
| Sarpogrelate hydrochloride |
|
| Selective beta-2-adrenoreceptor agonists |
|
| Selegiline hydrochloride |
|
| Seretide mite |
|
| Sertraline |
|
| Sibutramine |
|
| Sildenafil citrate |
|
| Silymarin |
|
| Simvastatin |
|
| Sinemet |
|
| Sinilgel |
|
| Sitagliptin |
|
| Sodium chloride |
|
| Sotalol hydrochloride |
|
| Spironolactone |
|
| Streptomycin |
|
| Sucralfate |
|
| Sulglicotide |
|
| Sulodexide |
|
| Symbicort turbuhaler "draco" |
|
| Tamsulosin |
|
| Tamsulosin hydrochloride |
|
| Tazobactam sodium |
|
| Telmisartan |
|
| Terazosin |
|
| Terazosin hydrochloride |
|
| Terbutaline sulfate |
|
| Theophylline |
|
| Thiamazole |
|
| Thioctic acid |
|
| Throat preparations |
|
| Tianeptine |
|
| Ticlopidine |
|
| Tiotropium |
|
| Tiotropium bromide |
|
| Tiotropium bromide/formoterol fumarate |
|
| Tiropramide hydrochloride |
|
| Tocopherol |
|
| Tramadol hydrochloride |
|
| Tranexamic acid |
|
| Travad phosphate enema |
|
| Trazodone |
|
| Triaprin |
|
| Triflusal |
|
| Trimetazidine |
|
| Trimetazidine hydrochloride |
|
| Udenafil |
|
| Ultracet |
|
| Ursodeoxycholic acid |
|
| Valproate semisodium |
|
| Valsartan |
|
| Verapamil |
|
| Vildagliptin |
|
| Vitamins |
|
| Vitamins with minerals |
|
| Voglibose |
|
| Warfarin |
|
| Yeast |
|
| Zevit |
|
| Zolpidem |
|
| Zolpidem tartrate |
|
| Arrhythmia |
|
| Arteriosclerosis coronary artery |
|
| Atrial fibrillation |
|
| Bundle branch block right |
|
| Cardiac failure |
|
| Cardiac failure congestive |
|
| Cardiac valve disease |
|
| Congestive cardiomyopathy |
|
| Cor pulmonale chronic |
|
| Coronary artery disease |
|
| Coronary artery stenosis |
|
| Left ventricular hypertrophy |
|
| Mitral valve calcification |
|
| Myocardial infarction |
|
| Myocardial ischaemia |
|
| Prinzmetal angina |
|
| Sinus tachycardia |
|
| Ventricular extrasystoles |
|
| Hearing impaired |
|
| Basedow's disease |
|
| Goitre |
|
| Hyperthyroidism |
|
| Hypothyroidism |
|
| Thyroid cyst |
|
| Blindness unilateral |
|
| Visual impairment |
|
| Abdominal discomfort |
|
| Abdominal pain upper |
|
| Colitis |
|
| Colonic polyp |
|
| Constipation |
|
| Crohn's disease |
|
| Diverticulum intestinal |
|
| Duodenal ulcer |
|
| Duodenitis |
|
| Dyspepsia |
|
| Gastric haemorrhage |
|
| Gastric ulcer |
|
| Gastritis |
|
| Gastritis atrophic |
|
| Gastritis erosive |
|
| Gastrooesophageal reflux disease |
|
| Haemorrhoids |
|
| Intestinal polyp |
|
| Irritable bowel syndrome |
|
| Nausea |
|
| Oesophagitis |
|
| Pancreatitis |
|
| Pancreatitis chronic |
|
| Peptic ulcer |
|
| Periodontitis |
|
| Reflux oesophagitis |
|
| Chest pain |
|
| Fatigue |
|
| Malaise |
|
| Pain |
|
| Alcoholic liver disease |
|
| Cholecystitis |
|
| Cholelithiasis |
|
| Chronic hepatitis |
|
| Hepatic cyst |
|
| Hepatic steatosis |
|
| Hepatitis |
|
| Hepatitis alcoholic |
|
| Behcet's syndrome |
|
| Sarcoidosis |
|
| Appendicitis |
|
| Body tinea |
|
| Bronchiectasis |
|
| Bronchitis |
|
| Chronic sinusitis |
|
| Cystitis |
|
| Helicobacter infection |
|
| Hepatitis B |
|
| Lower respiratory tract infection |
|
| Lung abscess |
|
| Nasopharyngitis |
|
| Onychomycosis |
|
| Pharyngitis |
|
| Pneumonia |
|
| Pulmonary tuberculosis |
|
| Pyelonephritis acute |
|
| Rhinitis |
|
| Tinea pedis |
|
| Tonsillitis |
|
| Tuberculosis |
|
| Tuberculosis gastrointestinal |
|
| Tuberculous pleurisy |
|
| Upper respiratory tract infection |
|
| Meniscus lesion |
|
| Blood cholesterol increased |
|
| Blood viscosity increased |
|
| HIV test positive |
|
| Hepatitis B virus test |
|
| Liver function test abnormal |
|
| Calcium deficiency |
|
| Diabetes mellitus |
|
| Dyslipidaemia |
|
| Gout |
|
| Hypercholesterolaemia |
|
| Hyperhomocysteinaemia |
|
| Hyperlipidaemia |
|
| Hyperuricaemia |
|
| Impaired fasting glucose |
|
| Iron deficiency |
|
| Obesity |
|
| Ankylosing spondylitis |
|
| Arthritis |
|
| Back pain |
|
| Intervertebral disc disorder |
|
| Neck pain |
|
| Osteoarthritis |
|
| Osteopenia |
|
| Osteoporosis |
|
| Rheumatoid arthritis |
|
| Acute lymphocytic leukaemia |
|
| Benign lung neoplasm |
|
| Brain neoplasm |
|
| Cervix carcinoma |
|
| Extranodal marginal zone B-cell lymphoma |
|
| Gastric adenoma |
|
| Gastric cancer |
|
| Head and neck cancer |
|
| Hepatic neoplasm malignant |
|
| Histiocytosis haematophagic |
|
| Laryngeal cancer |
|
| Leiomyosarcoma |
|
| Lung neoplasm |
|
| Lung neoplasm malignant |
|
| Prostate cancer |
|
| Rectal cancer |
|
| Renal cancer |
|
| Renal cell carcinoma |
|
| Renal neoplasm |
|
| Carotid artery occlusion |
|
| Carotid artery stenosis |
|
| Cerebral arteriosclerosis |
|
| Cerebral infarction |
|
| Cerebral ischaemia |
|
| Cerebrovascular accident |
|
| Dementia |
|
| Dizziness |
|
| Headache |
|
| Myasthenia gravis |
|
| Neuropathy peripheral |
|
| Parkinson's disease |
|
| Sedation |
|
| Transient ischaemic attack |
|
| Alcohol abuse |
|
| Bipolar disorder |
|
| Depressed mood |
|
| Depression |
|
| Dysthymic disorder |
|
| Generalised anxiety disorder |
|
| Insomnia |
|
| Major depression |
|
| Obsessive-compulsive disorder |
|
| Panic attack |
|
| Panic disorder |
|
| Personality disorder |
|
| Psychotic disorder |
|
| Schizoaffective disorder |
|
| Schizophrenia |
|
| Sleep disorder |
|
| Social phobia |
|
| Substance abuse |
|
| Bladder irritation |
|
| Nephrolithiasis |
|
| Proteinuria |
|
| Renal failure chronic |
|
| Benign prostatic hyperplasia |
|
| Erectile dysfunction |
|
| Organic erectile dysfunction |
|
| Asthma |
|
| Bronchitis chronic |
|
| Chronic obstructive pulmonary disease |
|
| Cough |
|
| Dyspnoea |
|
| Emphysema |
|
| Epistaxis |
|
| Haemoptysis |
|
| Idiopathic pulmonary fibrosis |
|
| Interstitial lung disease |
|
| Pleural effusion |
|
| Pneumothorax |
|
| Pulmonary bulla |
|
| Pulmonary embolism |
|
| Pulmonary mass |
|
| Respiratory disorder |
|
| Rhinitis allergic |
|
| Sleep apnoea syndrome |
|
| Snoring |
|
| Acne |
|
| Alopecia areata |
|
| Dermatitis contact |
|
| Pruritus |
|
| Urticaria |
|
| Alcoholic |
|
| Aortic valve replacement |
|
| Haemorrhoid operation |
|
| Arteriosclerosis |
|
| Hypertension |
|
| Peripheral vascular disorder |
|
| Thromboangiitis obliterans |
|
| Vasculitis |
|
|
|
|
|
|
|
|
| Title |
|---|
| Denominators |
|---|
| Categories |
|---|
| Acamprosate |
| |||||
| Acarbose |
| |||||
| Aceclofenac |
| |||||
| Acetylcarnitine |
| |||||
| Acetylcysteine |
| |||||
| Acetylsalicylic acid |
| |||||
| Acetylsalicylic acid/atorvastatin/ramipril |
| |||||
| Acetylsalicylic acid/clopidogrel |
| |||||
| Adenine/biphenyldimethyldicarboxylate/vitamins |
| |||||
| Albumin human |
| |||||
| Alfuzosin |
| |||||
| All other therapeutic products |
| |||||
| Allopurinol |
| |||||
| Almagate |
| |||||
| Almagel |
| |||||
| Alprazolam |
| |||||
| Aluminum hydroxide/magnesium carbonate |
| |||||
| Amantadine hydrochloride / paracetamol |
| |||||
| Ambroxol |
| |||||
| Ambroxol acefyllinate |
| |||||
| Ambroxol hydrochloride |
| |||||
| Amikacin |
| |||||
| Amino acids |
| |||||
| Amino acids NOS/carbohydrates NOS/electrolytes NOS |
| |||||
| Aminophylline |
| |||||
| Amisulpride |
| |||||
| Amitriptyline hydrochloride |
| |||||
| Amlodipine |
| |||||
| Amlodipine besilate |
| |||||
| Amlodipine besilate/atorvastatin calcium |
| |||||
| Amlodipine besilate/valsartan |
| |||||
| Amlodipine camsilate |
| |||||
| Amlodipine maleate |
| |||||
| Amlodipine orotate |
| |||||
| Amlodipine/valsartan |
| |||||
| Ammonium Cl/chlorpheniramine maleate |
| |||||
| Amoxicillin |
| |||||
| Amoxicillin sodium |
| |||||
| Anisodamine |
| |||||
| Antacids |
| |||||
| Antidiarrhoeal microorganisms |
| |||||
| Antisterone |
| |||||
| Aripiprazole |
| |||||
| Aronamin gold |
| |||||
| Arotinolol hydrochloride |
| |||||
| Artemisia asiatica |
| |||||
| Artemisia asiatica/ethanol |
| |||||
| Asasantin |
| |||||
| Asmeton |
| |||||
| Atenolol |
| |||||
| Atorvastatin |
| |||||
| Atorvastatin calcium |
| |||||
| Atorvastatin/fenofibrate |
| |||||
| Azathioprine |
| |||||
| Azelastine |
| |||||
| Azelastine hydrochloride |
| |||||
| Azithromycin |
| |||||
| Aztreonam |
| |||||
| B-komplex "leciva" |
| |||||
| Bambuterol hydrochloride |
| |||||
| Becosules syrup |
| |||||
| Becosym forte |
| |||||
| Becotal |
| |||||
| Benazepril |
| |||||
| Benazepril hydrochloride |
| |||||
| Benexate hydrochloride |
| |||||
| Benproperine |
| |||||
| Benproperine phosphate |
| |||||
| Benzodiazepine derivatives |
| |||||
| Bepotastine besilate |
| |||||
| Beraprost |
| |||||
| Beraprost sodium |
| |||||
| Berberine |
| |||||
| Beszyme |
| |||||
| Betahistine |
| |||||
| Bevantolol |
| |||||
| Biselect |
| |||||
| Bismuth subcitrate tripotassium |
| |||||
| Bismuth subcitrate tripotassium/ranitidine HCl |
| |||||
| Bisoprolol |
| |||||
| Bisoprolol fumarate |
| |||||
| Borneol/notoginseng/salvia miltiorrhiza |
| |||||
| Bromelains/dehydrocholic/pancreatin/simeticone |
| |||||
| Bromhexine |
| |||||
| Broncho-vaxom |
| |||||
| Budesonide |
| |||||
| Bufferin |
| |||||
| Bupropion |
| |||||
| Bupropion hydrochloride |
| |||||
| Buspiron |
| |||||
| Buspirone |
| |||||
| Calcitriol / calcium citrate |
| |||||
| Calcium citrate/colecalciferol |
| |||||
| Calcium lactate |
| |||||
| Candesartan |
| |||||
| Candesartan cilexetil |
| |||||
| Carbazochrome |
| |||||
| Cardiovascular system drugs |
| |||||
| Carvedilol |
| |||||
| Cefaclor |
| |||||
| Cefalexin |
| |||||
| Cefcapene pivoxil hydrochloride |
| |||||
| Cefixime |
| |||||
| Cefoperazone sodium |
| |||||
| Cefpodoxime |
| |||||
| Cefpodoxime proxetil |
| |||||
| Cefradine |
| |||||
| Ceftriaxone |
| |||||
| Ceftriaxone sodium |
| |||||
| Cefuroxime |
| |||||
| Cefuroxime axetil |
| |||||
| Cefuroxime sodium |
| |||||
| Celecoxib |
| |||||
| Cephalosporins and related substances |
| |||||
| Cetirizine |
| |||||
| Chlordiazepoxide/clidinium bromide/dicycloverine |
| |||||
| Chlormadinone acetate |
| |||||
| Chlorphenamine maleate |
| |||||
| Chlorphenesin carbamate |
| |||||
| Choline alfoscerate |
| |||||
| Chondroitin/glucosamine |
| |||||
| Cilazapril |
| |||||
| Cilnidipine |
| |||||
| Cilostazol |
| |||||
| Cimetidine |
| |||||
| Cimetropium bromide |
| |||||
| Cinnarizine |
| |||||
| Ciprofloxacin |
| |||||
| Ciprofloxacin hydrochloride |
| |||||
| Citalopram |
| |||||
| Citicoline |
| |||||
| Clarithromycin |
| |||||
| Clavulin |
| |||||
| Clobazam |
| |||||
| Clonazepam |
| |||||
| Clopidogrel |
| |||||
| Clopidogrel sulfate |
| |||||
| Co-diovan |
| |||||
| Colchicine |
| |||||
| Cordalin/old form/ |
| |||||
| Cotylenol |
| |||||
| Cough syrup |
| |||||
| Cyproterone acetate |
| |||||
| Desmopressin |
| |||||
| Desonide |
| |||||
| Dexamethasone |
| |||||
| Dexamethasone/neomycin sulfate/polymyxin B sulfate |
| |||||
| Diazepam |
| |||||
| Diclofenac |
| |||||
| Digoxin |
| |||||
| Dihydrocodeine bitartrate |
| |||||
| Diloxanide furoate/metronidazole |
| |||||
| Diltiazem |
| |||||
| Diltiazem hydrochloride |
| |||||
| Dimenhydrinate |
| |||||
| Disulfiram |
| |||||
| Docetaxel |
| |||||
| Domperidone |
| |||||
| Domperidone maleate |
| |||||
| Domperidone/pantoprazole |
| |||||
| Domperidone/rabeprazole |
| |||||
| Domperidone/rabeprazole sodium |
| |||||
| Donepezil |
| |||||
| Doxazosin |
| |||||
| Doxazosin mesilate |
| |||||
| Doxofylline |
| |||||
| Drotaverine |
| |||||
| Drug, unspecified |
| |||||
| Duloxetine |
| |||||
| Duloxetine hydrochloride |
| |||||
| Ebastine |
| |||||
| Ecabet monosodium |
| |||||
| Efavirenz/emtricitabine/tenofovir |
| |||||
| Efonidipine |
| |||||
| Enalapril |
| |||||
| Enalapril maleate |
| |||||
| Epoprostenol |
| |||||
| Eprosartan |
| |||||
| Eprosartan mesilate |
| |||||
| Eprosartan mesilate/hydrochlorothiazide |
| |||||
| Erdosteine |
| |||||
| Ergenyl chrono |
| |||||
| Erlotinib hydrochloride |
| |||||
| Erythromycin ethylsuccinate |
| |||||
| Escitalopram |
| |||||
| Esomeprazole |
| |||||
| Esomeprazole magnesium |
| |||||
| Estazolam |
| |||||
| Etizolam |
| |||||
| Etoposide |
| |||||
| Etoricoxib |
| |||||
| Ezetimibe |
| |||||
| Ezetimibe/simvastatin |
| |||||
| Famotidine |
| |||||
| Felodipine |
| |||||
| Fenofibrate |
| |||||
| Ferric hydroxide polymaltose complex |
| |||||
| Ferrous sulfate |
| |||||
| Fexofenadine |
| |||||
| Fexofenadine hydrochloride |
| |||||
| Fish oil |
| |||||
| Flunarizine |
| |||||
| Fluoxetine |
| |||||
| Fluoxetine hydrochloride |
| |||||
| Fluticasone propionate |
| |||||
| Fluvastatin |
| |||||
| Folic acid |
| |||||
| Folic acid/mecobalamin/pyridoxine hydrochloride |
| |||||
| Foraseq |
| |||||
| Formoterol |
| |||||
| Formoterol fumarate |
| |||||
| Fosinopril |
| |||||
| Fosinopril sodium |
| |||||
| Furosemide |
| |||||
| Gabapentin |
| |||||
| Galenic /fluticasone/salmeterol |
| |||||
| Galenic /salbutamol/guaifenesin |
| |||||
| General nutrients/minerals/vitamins |
| |||||
| Ginkgo biloba |
| |||||
| Ginkgo biloba extract |
| |||||
| Glibenclamide |
| |||||
| Gliclazide |
| |||||
| Glimepiride |
| |||||
| Glimepiride/metformin |
| |||||
| Glimepiride/metformin hydrochloride |
| |||||
| Glipizide |
| |||||
| Gliquidone |
| |||||
| Glucose |
| |||||
| Glyceryl trinitrate |
| |||||
| Guaifenesin |
| |||||
| Hedera helix |
| |||||
| Heparin-fraction |
| |||||
| Hepatitis B vaccine |
| |||||
| Herbal preparation |
| |||||
| Homeopatic preparation |
| |||||
| Hyaluronate sodium |
| |||||
| Hydrochlorothiazide |
| |||||
| Hydrotalcite |
| |||||
| Hydroxychloroquine |
| |||||
| Hydroxyzine |
| |||||
| Hydroxyzine hydrochloride |
| |||||
| Hyoscine butylbromide |
| |||||
| Hyzaar |
| |||||
| I.v. solutions |
| |||||
| Ibuprofen |
| |||||
| Indapamide |
| |||||
| Indometacin |
| |||||
| Infliximab |
| |||||
| Inosine |
| |||||
| Insulin |
| |||||
| Insulin aspart |
| |||||
| Insulin glargine |
| |||||
| Insulin glulisine |
| |||||
| Insulin human |
| |||||
| Insulin human injection, isophane |
| |||||
| Ipratropium |
| |||||
| Ipratropium bromide |
| |||||
| Irbesartan |
| |||||
| Isoconazole nitrate |
| |||||
| Isosorbide dinitrate |
| |||||
| Isosorbide mononitrate |
| |||||
| Isotretinoin |
| |||||
| Ispaghula |
| |||||
| Ispaghula husk |
| |||||
| Itavastatin |
| |||||
| Itopride |
| |||||
| Itopride hydrochloride |
| |||||
| Itraconazole |
| |||||
| Karvea hct |
| |||||
| Kombipak II |
| |||||
| Lacidipine |
| |||||
| Lactitol |
| |||||
| Lactulose |
| |||||
| Lamivudine |
| |||||
| Lansoprazole |
| |||||
| Lekovit Ca |
| |||||
| Lenograstim |
| |||||
| Lercanidipine |
| |||||
| Lercanidipine hydrochloride |
| |||||
| Levamlodipine besylate |
| |||||
| Levocarnitine |
| |||||
| Levocetirizine |
| |||||
| Levocetirizine dihydrochloride |
| |||||
| Levocetirizine dihydrochloride/montelukast sodium |
| |||||
| Levocloperastine fendizoate |
| |||||
| Levodropropizine |
| |||||
| Levofloxacin |
| |||||
| Levofloxacin hydrochloride |
| |||||
| Levosalbutamol hydrochloride |
| |||||
| Levosulpiride |
| |||||
| Levothyroxine sodium |
| |||||
| Lipase |
| |||||
| Lisinopril |
| |||||
| Lithium carbonate |
| |||||
| Loperamide |
| |||||
| Loratadine |
| |||||
| Lorazepam |
| |||||
| Losartan |
| |||||
| Losartan potassium |
| |||||
| Magnesium hydroxide |
| |||||
| Magnesium oxide |
| |||||
| Mecobalamin |
| |||||
| Medilac-S |
| |||||
| Mefloquine |
| |||||
| Megestrol acetate |
| |||||
| Meprobamate |
| |||||
| Meropenem |
| |||||
| Mesalazine |
| |||||
| Metformin |
| |||||
| Metformin hydrochloride |
| |||||
| Metformin hydrochloride/rosiglitazone |
| |||||
| Metformin hydrochloride/sitagliptin |
| |||||
| Methoxyphenamine |
| |||||
| Methylprednisolone |
| |||||
| Metoclopramide |
| |||||
| Metoclopramide hydrochloride |
| |||||
| Metoprolol |
| |||||
| Metoprolol succinate |
| |||||
| Metoprolol tartrate |
| |||||
| Metronidazole |
| |||||
| Milnacipran |
| |||||
| Milnacipran hydrochloride |
| |||||
| Mirtazapine |
| |||||
| Mobizox |
| |||||
| Molsidomine |
| |||||
| Mometasone |
| |||||
| Mometasone furoate |
| |||||
| Montelukast |
| |||||
| Montelukast sodium |
| |||||
| Mosapride |
| |||||
| Mosapride citrate |
| |||||
| Moxifloxacin |
| |||||
| Moxifloxacin hydrochloride |
| |||||
| Mucaine |
| |||||
| Multivitamins with minerals |
| |||||
| Multivitamins, plain |
| |||||
| Myprodol "rio ethicals" |
| |||||
| Myrin plus |
| |||||
| Myrtol |
| |||||
| Naltrexone |
| |||||
| Naproxen |
| |||||
| Nateglinide |
| |||||
| Nebivolol |
| |||||
| Nicorandil |
| |||||
| Nicotine |
| |||||
| Nicotinic acid |
| |||||
| Nifedipine |
| |||||
| Nimesulide/paracetamol |
| |||||
| Nimodipine |
| |||||
| Nisoldipine |
| |||||
| Nitrendipine |
| |||||
| Nizatidine |
| |||||
| Ofloxacin |
| |||||
| Olanzapine |
| |||||
| Olmesartan |
| |||||
| Olmesartan medoxomil |
| |||||
| Omega-3 marine triglycerides |
| |||||
| Omega-3 triglycerides |
| |||||
| Omeprazole |
| |||||
| Ondansetron |
| |||||
| Ondansetron hydrochloride |
| |||||
| Orlistat |
| |||||
| Oxazepam |
| |||||
| Oxcarbazepine |
| |||||
| Oxycodone |
| |||||
| Oxycodone hydrochloride |
| |||||
| Palonosetron hydrochloride |
| |||||
| Pantoprazole |
| |||||
| Pantoprazole sodium |
| |||||
| Paracetamol |
| |||||
| Paroxetine |
| |||||
| Paroxetine hydrochloride |
| |||||
| Pentamycin |
| |||||
| Perindopril |
| |||||
| Phenylephrine/triprolidine |
| |||||
| Phenytoin sodium |
| |||||
| Phosphatidyl choline |
| |||||
| Phytomenadione |
| |||||
| Pinaverium bromide |
| |||||
| Pioglitazone |
| |||||
| Pioglitazone hydrochloride |
| |||||
| Platelets, human blood |
| |||||
| Pneumococcal vaccine |
| |||||
| Polycarbophil calcium |
| |||||
| Pramipexole |
| |||||
| Pranlukast hydrate |
| |||||
| Pravastatin |
| |||||
| Pravastatin sodium |
| |||||
| Prednicarbate |
| |||||
| Prednisolone |
| |||||
| Pregabalin |
| |||||
| Procaterol |
| |||||
| Promethazine |
| |||||
| Pronase |
| |||||
| Propranolol |
| |||||
| Propranolol hydrochloride |
| |||||
| Propylthiouracil |
| |||||
| Pseudoephedrine hydrochloride |
| |||||
| Pyridostigmine bromide |
| |||||
| Pyridoxine hydrochloride |
| |||||
| Quetiapine fumarate |
| |||||
| Rabeprazole |
| |||||
| Rabeprazole sodium |
| |||||
| Raloxifene |
| |||||
| Ramipril |
| |||||
| Ranitidine |
| |||||
| Ranitidine hydrochloride |
| |||||
| Rebamipide |
| |||||
| Repaglinide |
| |||||
| Rino ebastel |
| |||||
| Riopan plus |
| |||||
| Risedronic acid |
| |||||
| Risperidone |
| |||||
| Rosiglitazone maleate |
| |||||
| Rosuvastatin |
| |||||
| Rosuvastatin calcium |
| |||||
| Roxithromycin |
| |||||
| Salbutamol |
| |||||
| Salbutamol sulfate |
| |||||
| Salmeterol |
| |||||
| Salmeterol xinafoate |
| |||||
| Salvia miltiorrhiza |
| |||||
| Sarpogrelate |
| |||||
| Sarpogrelate hydrochloride |
| |||||
| Selective beta-2-adrenoreceptor agonists |
| |||||
| Selegiline hydrochloride |
| |||||
| Seretide "allen & hanburys ltd" |
| |||||
| Seretide mite |
| |||||
| Sertraline |
| |||||
| Sibutramine |
| |||||
| Sibutramine hydrochloride |
| |||||
| Sildenafil citrate |
| |||||
| Silymarin |
| |||||
| Simeco |
| |||||
| Simvastatin |
| |||||
| Sinemet |
| |||||
| Sirolin retard |
| |||||
| Sitagliptin |
| |||||
| Sodium chloride |
| |||||
| Sotalol hydrochloride |
| |||||
| Spedifen |
| |||||
| Spirapril hydrochloride |
| |||||
| Spironolactone |
| |||||
| Spironolactone / torasemide |
| |||||
| Streptomycin |
| |||||
| Sucralfate |
| |||||
| Sulglicotide |
| |||||
| Sulodexide |
| |||||
| Symbicort turbuhaler "draco" |
| |||||
| Tadalafil |
| |||||
| Tamsulosin |
| |||||
| Tamsulosin hydrochloride |
| |||||
| Tazobactam sodium |
| |||||
| Telmisartan |
| |||||
| Terazosin |
| |||||
| Terazosin hydrochloride |
| |||||
| Terbinafine hydrochloride |
| |||||
| Terbutaline |
| |||||
| Terbutaline sulfate |
| |||||
| Testosterone undecanoate |
| |||||
| Theophylline |
| |||||
| Thiamazole |
| |||||
| Thioctic acid |
| |||||
| Throat preparations |
| |||||
| Tianeptine |
| |||||
| Ticlopidine |
| |||||
| Tiotropium |
| |||||
| Tiotropium bromide |
| |||||
| Tiotropium bromide/formoterol fumarate |
| |||||
| Tiropramide hydrochloride |
| |||||
| Tocopherol |
| |||||
| Tolterodine |
| |||||
| Tramadol |
| |||||
| Tramadol hydrochloride |
| |||||
| Tranexamic acid |
| |||||
| Trazodone |
| |||||
| Triaprin |
| |||||
| Triazolam |
| |||||
| Triflusal |
| |||||
| Trihexyphenidyl |
| |||||
| Trimebutine |
| |||||
| Trimebutine maleate |
| |||||
| Trimetazidine |
| |||||
| Trimetazidine hydrochloride |
| |||||
| Tromcardin |
| |||||
| Udenafil |
| |||||
| Ultracet |
| |||||
| Ursodeoxycholic acid |
| |||||
| Valproate semisodium |
| |||||
| Valsartan |
| |||||
| Varidase |
| |||||
| Verapamil |
| |||||
| Vildagliptin |
| |||||
| Vitamin B |
| |||||
| Vitamins |
| |||||
| Vitamins with minerals |
| |||||
| Vitamins, other combinations |
| |||||
| Voglibose |
| |||||
| Warfarin |
| |||||
| Yeast |
| |||||
| Zevit |
| |||||
| Zinc |
| |||||
| Zoledronic acid |
| |||||
| Zolpidem |
| |||||
| Zolpidem tartrate |
|